萩原悠也先生（レジデント）がSecond authorの論文が公表

Nakasya A, Hagiwara Y, Ikoma T, Kurioka Y, Matsumoto T, Yamamoto Y, Tsuduki T, Kajiwara T, Moriwaki T, Nishina T, Yamashita N, Hyodo I.

”Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

Int J Clin Oncol. 2022 Jan 28. doi: 10.1007/s10147-022-02114-y. Online ahead of print.”